PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Enfusion, Inc. (ENFN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US2928121043

CUSIP

292812104

Sector

Technology

IPO Date

Oct 21, 2021

Highlights

Market Cap

$972.03M

EPS (TTM)

$0.04

PE Ratio

257.50

Total Revenue (TTM)

$148.67M

Gross Profit (TTM)

$100.20M

EBITDA (TTM)

$12.96M

Year Range

$7.52 - $11.38

Target Price

$9.89

Short %

1.78%

Short Ratio

1.83

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ENFN vs. SMCI
Popular comparisons:
ENFN vs. SMCI

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Enfusion, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%AugustSeptemberOctoberNovemberDecember2025
18.70%
5.96%
ENFN (Enfusion, Inc.)
Benchmark (^GSPC)

Returns By Period

Enfusion, Inc. had a return of -1.36% year-to-date (YTD) and 9.25% in the last 12 months.


ENFN

YTD

-1.36%

1M

-0.49%

6M

18.69%

1Y

9.25%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.47%

1M

-2.98%

6M

5.95%

1Y

24.05%

5Y*

12.57%

10Y*

11.22%

*Annualized

Monthly Returns

The table below presents the monthly returns of ENFN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-18.56%9.75%6.69%0.65%1.07%-9.46%11.27%-12.55%14.48%-6.11%11.56%3.62%6.19%
202322.85%-9.76%-2.05%-20.19%-5.01%40.95%-3.30%-21.29%5.04%-7.47%23.25%-5.18%0.31%
2022-34.05%20.13%-23.33%0.39%-14.25%-6.76%12.63%7.74%-0.40%14.83%-32.60%1.26%-53.82%
20214.14%-6.16%8.16%5.70%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ENFN is 56, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ENFN is 5656
Overall Rank
The Sharpe Ratio Rank of ENFN is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of ENFN is 5252
Sortino Ratio Rank
The Omega Ratio Rank of ENFN is 5151
Omega Ratio Rank
The Calmar Ratio Rank of ENFN is 5555
Calmar Ratio Rank
The Martin Ratio Rank of ENFN is 6060
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Enfusion, Inc. (ENFN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ENFN, currently valued at 0.32, compared to the broader market-4.00-2.000.002.000.322.03
The chart of Sortino ratio for ENFN, currently valued at 0.67, compared to the broader market-4.00-2.000.002.004.000.672.71
The chart of Omega ratio for ENFN, currently valued at 1.08, compared to the broader market0.501.001.502.001.081.37
The chart of Calmar ratio for ENFN, currently valued at 0.16, compared to the broader market0.002.004.006.000.163.04
The chart of Martin ratio for ENFN, currently valued at 1.18, compared to the broader market-10.000.0010.0020.001.1812.93
ENFN
^GSPC

The current Enfusion, Inc. Sharpe ratio is 0.32. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Enfusion, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
0.32
2.03
ENFN (Enfusion, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Enfusion, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-55.71%
-2.98%
ENFN (Enfusion, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Enfusion, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Enfusion, Inc. was 67.13%, occurring on May 16, 2023. The portfolio has not yet recovered.

The current Enfusion, Inc. drawdown is 55.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-67.13%Nov 15, 2021377May 16, 2023
-7.87%Oct 26, 20212Oct 27, 20218Nov 8, 202110
-0.4%Nov 9, 20211Nov 9, 20213Nov 12, 20214

Volatility

Volatility Chart

The current Enfusion, Inc. volatility is 11.98%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%AugustSeptemberOctoberNovemberDecember2025
11.98%
4.47%
ENFN (Enfusion, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Enfusion, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Enfusion, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab